Tests for suspected T-cell lymphoma: obtaining the right tissue and a usable diagnosis

The order of investigations should follow the questions that remain unanswered. An enlarged node, rash, or abnormal count can raise suspicion, but the team still needs to establish whether a neoplasm is present, identify the abnormal cells, classify the disease, and determine its distribution. Combining diagnosis, staging, and pretreatment safety assessment into an unexplained package can leave patients with many results and little understanding of what will change the next decision.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Describe the first abnormality, how it evolved, constitutional symptoms, and any skin or nasal complaints. Prior infections, autoimmune conditions, gastrointestinal disease, and immune-suppressing treatment may contribute relevant context. Anatomical sites can suggest particular T/NK entities, but a nasal lesion or an itchy skin patch is not a diagnosis in itself. Clinical clues must be matched to the tissue findings. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025
EBER testing examines viral-associated signals in tissue, whereas an EBV DNA measurement in blood addresses another aspect of assessment. They are not interchangeable, and a positive blood result does not independently diagnose NK/T-cell lymphoma. In relevant entities, viral findings contribute to diagnosis or monitoring. Retain the specimen type, units, and laboratory interpretation rather than reporting only that EBV was positive. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025
Send the complete pathology report, staining list, existing molecular and viral studies, and original imaging. Explain whether slides and blocks can be loaned for review. The receiving hospital can then assess whether expert interpretation, additional stains, a specialized test, or fresh tissue is needed. Ask it to connect each proposed addition with an unresolved clinical question instead of repeating the entire workup merely because care has crossed a border.

Quick answer

Full guide

Use the history and disease sites to plan sampling

Describe the first abnormality, how it evolved, constitutional symptoms, and any skin or nasal complaints. Prior infections, autoimmune conditions, gastrointestinal disease, and immune-suppressing treatment may contribute relevant context. Anatomical sites can suggest particular T/NK entities, but a nasal lesion or an itchy skin patch is not a diagnosis in itself. Clinical clues must be matched to the tissue findings. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

The largest lump is not necessarily the best biopsy target. The clinician considers access, imaging characteristics, possible necrosis, and procedural risk. If imaging has already been performed, provide the original files to the sampling and pathology teams. Planning before the procedure can improve the chance of obtaining representative material that supports the required studies.

Report prior steroids or anticancer treatment with the dates and actual doses. This does not automatically make a biopsy unhelpful, but the team should understand possible effects on symptoms and tissue. When urgent airway, neurological, or organ problems exist, clinicians must coordinate stabilization with diagnosis. Do not independently stop treatment prescribed for an emergency in an attempt to improve a future specimen.

Understand the limits of different biopsy approaches

When feasible, an excisional or incisional biopsy preserves tissue architecture that can be important in complex lymphoma classification. A core biopsy may be more appropriate for a deep lesion or a patient with greater surgical risk, but the pathologist must judge whether it answers the question. Fine needle cytomorphology alone has limitations. An inconclusive initial sample cannot simply exclude lymphoma when the clinical suspicion remains high. CAP/ASCP: Laboratory Workup of Lymphoma in Adults guideline

Ask whether material needs to be reserved for flow cytometry, molecular analysis, or microbiological testing. Different studies have different handling requirements, which the clinical and laboratory teams should coordinate. The patient should not be expected to divide the specimen. If slides or a block already exist, determine whether additional studies can use that material before repeating an invasive procedure.

Qualifications such as limited tissue, extensive necrosis, or a recommendation for further sampling should remain attached to the report. They describe evidential limitations and do not necessarily imply more aggressive disease. Ask what information is missing and how another sampling approach is expected to obtain it. That explanation allows a practical discussion of benefit and procedural burden.

Immunohistochemistry identifies patterns, not a score of positive markers

T-cell markers must be interpreted with morphology, distribution, and aberrant expression. Normal immune cells can be present around a neoplasm, so a positive T-cell stain does not prove that every suspicious cell belongs to a T-cell tumor. The pathologist needs to identify the actual lesional population and distinguish it from reactive and other cellular processes. Counting positive stains from an online list is not a reliable way to assess severity. Campo et al.: International Consensus Classification of Mature Lymphoid Neoplasms, 2022

CD30 can be expressed in anaplastic large cell lymphoma and in other entities. ALK findings, morphology, and clinical distribution help refine the interpretation. Suspected T-follicular-helper disease requires assessment of the appropriate phenotype and tissue pattern, sometimes with supporting molecular evidence. These tests contribute to the diagnosis as a whole rather than merely selecting a drug target. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

When two institutions use different terminology, ask a reviewing hematopathologist to explain the discrepancy using the original material. It may reflect an updated classification, a different degree of certainty, or additional evidence. Sending only the final diagnostic phrase for translation omits much of the information needed to resolve the issue. The descriptive report, staining results, and specimen date belong together.

Clonality and sequencing support interpretation without replacing it

T-cell receptor clonality can help the assessment, but must be related to morphology, phenotype, and the clinical situation. A detected clone is not an automatic diagnosis in every circumstance, and a negative result does not always exclude disease. Sample composition and analytical limitations matter. Ask the pathologist how the finding changes confidence in the specific diagnosis rather than treating it as a separate yes-or-no cancer test. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025 CAP/ASCP: Laboratory Workup of Lymphoma in Adults guideline

Sequencing may support a subtype or identify a possible treatment or research question. Not every alteration has a matching approved drug. Somatic changes found in a tumor are also different from testing intended to assess inherited susceptibility. Before a broad panel is ordered, establish its purpose, whether adequate material remains, and whether its result could affect the current decision. NCI: Biomarker Testing for Cancer Treatment

A large pan-cancer panel is not necessarily the next useful investigation when the basic lymphoma diagnosis remains uncertain. Some blood abnormalities may require interpretation in relation to other hematopoietic cell populations. Do not assume that every reported mutation belongs to one tumor simply because it appears in the same set of records. Complex results need an identified clinician or pathology team responsible for the final synthesis.

Distinguish viral findings in tissue from infection tests

EBER testing examines viral-associated signals in tissue, whereas an EBV DNA measurement in blood addresses another aspect of assessment. They are not interchangeable, and a positive blood result does not independently diagnose NK/T-cell lymphoma. In relevant entities, viral findings contribute to diagnosis or monitoring. Retain the specimen type, units, and laboratory interpretation rather than reporting only that EBV was positive. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

HTLV-1 assessment has a particular role when adult T-cell leukemia/lymphoma is suspected. WHO describes confirmation using an appropriate combination of screening and additional tests. A reactive screening result does not complete the entire diagnostic workup, and HTLV-1 does not explain every T-cell lymphoma. Questions about geographical history and exposure support medical interpretation and should be handled respectfully. WHO: Human T-lymphotropic virus-1, December 2025

Hepatitis B, hepatitis C, HIV, and other infection investigations may also be relevant to treatment safety. An abnormal screening test does not automatically prevent all lymphoma treatment; it establishes the need to clarify infection status and plan management. Share the findings with the hematology service so that separate prescribers know what prevention or treatment is being arranged.

Combine PET/CT and marrow assessment for the actual subtype

PET/CT often documents the distribution of FDG-avid systemic T-cell disease and provides a treatment baseline. Infection and inflammation can also cause uptake, so imaging does not establish tissue identity. A separate examination such as MRI may be needed to define local anatomy. The fact that PET has already been obtained does not make every other imaging study redundant. Cheson et al.: Lugano classification for lymphoma evaluation and response

Marrow aspiration and biopsy can provide important staging and diagnostic information in T-cell lymphoma. Rules permitting omission of marrow biopsy in selected other lymphomas should not be copied without considering histology. Ask whether the team is assessing lymphoma involvement, another marrow abnormality, or both. Explaining the question makes the reason for the procedure easier to understand. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

The CHEMO-T PET/CT substudy evaluated imaging within a defined PTCL treatment and marrow-assessment setting. Prognostic information from a study is different from permission to replace all investigations with one scan. When Lugano-based response methods are later used, original lesion information and images help the reporting team make a coherent comparison. Patients should not be left to decide treatment by comparing two SUV values alone. CHEMO-T investigators: PET/CT substudy in peripheral T-cell lymphoma, 2025 PRoLoG Consensus Initiative: clinical application of Lugano assessment

Ask whether the imaging center needs prior scans, recent treatment dates, and relevant symptoms before the appointment. A report that can be interpreted alongside the clinical course is more useful than a technically completed scan without context. Keep a copy of both the written conclusion and the digital images for any subsequent review.

Skin-dominant and blood-dominant presentations require adapted investigation

Skin disease may require coordination between dermatology and hematopathology, taking into account lesion type, distribution, duration, and sometimes repeated sampling. Assessment of mycosis fungoides and Sézary syndrome includes different skin and blood components. A photograph alone cannot reliably confirm or exclude them. If findings are not yet characteristic, ask which changes should be followed and when another biopsy would be useful. NCI PDQ: Mycosis Fungoides and Sézary Syndrome Treatment

When abnormal circulating cells are prominent, blood morphology, flow cytometry, and related studies may play a larger role. Establishing whether a process involves mature T cells or precursor cells is important for the treatment pathway. This distinction is particularly relevant when reviewing records for a younger patient: a shared letter T does not make lymphoblastic and mature peripheral disease interchangeable. NCI PDQ: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment

Tests may therefore differ between patients without either workup being incomplete. A sensible explanation connects the chosen sample and method to the presentation. Ask for that reasoning if another patient's checklist looks different from yours, rather than requesting every test from both lists.

Before repeating investigations in China, identify the remaining gap

Send the complete pathology report, staining list, existing molecular and viral studies, and original imaging. Explain whether slides and blocks can be loaned for review. The receiving hospital can then assess whether expert interpretation, additional stains, a specialized test, or fresh tissue is needed. Ask it to connect each proposed addition with an unresolved clinical question instead of repeating the entire workup merely because care has crossed a border.

An estimate should separate the biopsy procedure, pain control or anesthesia, routine pathology, additional stains, molecular testing, and imaging. Keep unconfirmed items open until the required scope is known. A pathology-review fee should not be assumed to include every ancillary test. If an external laboratory will be involved, ask the clinician what can proceed while waiting and how clinical deterioration will be managed, without expecting a universal number of days to diagnosis.

At the final diagnostic discussion, distinguish established findings, meaningful uncertainties, and information that does not affect the immediate decision. Request a clear account of which entity the evidence supports, what result is still needed, and when the next review will occur. That synthesis makes the investigations usable for treatment planning and helps the family understand why each step was undertaken.